Sylvain Marchand-adam

List of Publications by Year
in descending order

95 papers	4,951 citations	100601 38 h-index	116156 66 g-index
101 all docs	101 docs citations	101 times ranked	7483 citing authors

#	Article	IF	Citations
1	Inhibition of the Arp2/3 complex represses human lung myofibroblast differentiation and attenuates bleomycinâ€induced pulmonary fibrosis. British Journal of Pharmacology, 2022, 179, 125-140.	2.7	4
2	Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort. Advances in Therapy, 2022, 39, 405-420.	1.3	2
3	Methotrexate and rheumatoid arthritis associated interstitial lung disease. European Respiratory Journal, 2021, 57, 2000337.	3.1	114
4	Impulse oscillometry and spirometry measurements relative to personal best values at the time of acute exacerbations of cystic fibrosis in adults. Clinical Physiology and Functional Imaging, 2021, 41, 76-84.	0.5	2
5	Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 245-249.	2.5	51
6	Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. European Respiratory Journal, 2021, 57, 2003198.	3.1	36
7	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology, 2021, 60, 359-365.	0.9	27
8	Transcutaneous PCO 2 â€based dead space ventilation at submaximal exercise accurately discriminates healthy controls from patients with chronic obstructive pulmonary disease. Clinical Physiology and Functional Imaging, 2021, 41, 253-261.	0.5	0
9	Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 807-816.	0.5	11
10	Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover. Respiratory Medicine, 2021, 183, 106415.	1.3	13
11	Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia. European Respiratory Journal, 2021, 57, 2003755.	3.1	27
12	ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution (TOUPIE): research protocol of a multicentric prospective study. BMJ Open, 2021, 11, e039078.	0.8	0
13	Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?. Journal of Medicinal Chemistry, 2020, 63, 13258-13265.	2.9	49
14	Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 709-716.	5.2	83
15	Lung function in Birt-Hogg-DubÃ© syndrome: a retrospective analysis of 96 patients. Orphanet Journal of Rare Diseases, 2020, 15, 120.	1.2	15
16	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	5.2	65
17	Women and COPD: do we need more evidence?. European Respiratory Review, 2019, 28, 180055.	3.0	85
18	A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT. Respiration, 2019, 98, 19-28.	1.2	15

#	Article	IF	Citations
19	Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors. Cancer Medicine, 2019, 8, 1486-1499.	1.3	13
20	Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. European Respiratory Journal, 2018, 51, 1701875.	3.1	34
21	Exploiting the S4â€“S5 Specificity of Human Neutrophil Proteinase 3 to Improve the Potency of Peptidyl Di(chlorophenyl)-phosphonate Ester Inhibitors: A Kinetic and Molecular Modeling Analysis. Journal of Medicinal Chemistry, 2018, 61, 1858-1870.	2.9	14
22	Physiology of the lung in idiopathic pulmonary fibrosis. European Respiratory Review, 2018, 27, 170062.	3.0	159
23	Rituximab for auto-immune alveolar proteinosis, a real life cohort study. Respiratory Research, 2018, 19, 74.	1.4	32
24	Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. Thorax, 2018, 73, 145-150.	2.7	140
25	MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. New England Journal of Medicine, 2018, 379, 2209-2219.	13.9	326
26	Therapeutic targeting of cathepsin C: from pathophysiology to treatment. , 2018, 190, 202-236.		85
27	Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis. Journal of Biological Chemistry, 2018, 293, 12415-12428.	1.6	26
28	Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia Syndrome Treated With Sirolimus. Annals of Internal Medicine, 2018, 169, 197.	2.0	7
29	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. Targeted Oncology, 2018, 13, 509-515.	1.7	30
30	A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 230-238.	0.2	2
31	Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases. Biochemical Pharmacology, 2017, 131, 52-67.	2.0	34
32	Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1602314.	3.1	154
33	Efficacy and Tolerance of Antiâ€“Tumor Necrosis Factor Î± Agents in Cutaneous Sarcoidosis. JAMA Dermatology, 2017, 153, 681.	2.0	46
34	Heterogeneity of lung disease associated with NK2 homeobox 1 mutations. Respiratory Medicine, 2017, 129, 16-23.	1.3	54
35	Organizing pneumonia and occupational and environmental risk factors: a caseâ€“control study. International Archives of Occupational and Environmental Health, 2017, 90, 865-871.	1.1	1
36	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews, 2017, 16, 1-9.	2.5	140

#	Article	IF	Citations
37	Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France. BMJ Open, 2017, 7, e018884.	0.8	26
38	Transcriptome of Cultured Lung Fibroblasts in Idiopathic Pulmonary Fibrosis: Meta-Analysis of Publically Available Microarray Datasets Reveals Repression of Inflammation and Immunity Pathways. International Journal of Molecular Sciences, 2016, 17, 2091.	1.8	28
39	Discordance in cathepsin B and cystatin C expressions in bronchoalveolar fluids between murine bleomycin-induced fibrosis and human idiopathic fibrosis. Respiratory Research, 2016, 17, 118.	1.4	11
40	Analysis of urinary cathepsin C for diagnosing Papillonâ€“LefÃ¨vre syndrome. FEBS Journal, 2016, 283, 498-509.	2.2	14
41	Prevalence and characteristics ofTERTandTERCmutations in suspected genetic pulmonary fibrosis. European Respiratory Journal, 2016, 48, 1721-1731.	3.1	136
42	Hiatal hernia on thoracic computed tomography in pulmonary fibrosis. European Respiratory Journal, 2016, 48, 833-842.	3.1	45
43	Neutrophilic Cathepsin C Is Maturated by a Multistep Proteolytic Process and Secreted by Activated Cells during Inflammatory Lung Diseases. Journal of Biological Chemistry, 2016, 291, 8486-8499.	1.6	45
44	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss). European Respiratory Journal, 2016, 48, 1429-1441.	3.1	102
45	Asthma and Hypogammaglobulinemia: an Asthma Phenotype with Low Type 2 Inflammation. Journal of Clinical Immunology, 2016, 36, 810-817.	2.0	16
46	Pulmonary manifestations of SjÃ¶gren's syndrome. European Respiratory Review, 2016, 25, 110-123.	3.0	206
47	Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Research, 2015, 1, 00032-2015.	1.1	12
48	Primary SjÃ¶gren's syndrome and occupational risk factors: A caseâ€“control study. Journal of Autoimmunity, 2015, 60, 80-85.	3.0	22
49	Cysteine cathepsins and cystatins: from ancillary tasks to prominent status in lung diseases. Biological Chemistry, 2015, 396, 111-130.	1.2	40
50	Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. Tumor Biology, 2015, 36, 4979-4986.	0.8	17
51	Gastroesophageal Reflux Disease Is a Risk Factor for Severity of Organizing Pneumonia. Respiration, 2015, 89, 119-126.	1.2	11
52	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. Journal of Autoimmunity, 2015, 65, 49-55.	3.0	34
53	Methacholine-Induced Variations in Airway Volume and the Slope of the Alveolar Capnogram Are Distinctly Associated with Airflow Limitation and Airway Closure. PLoS ONE, 2015, 10, e0143550.	1.1	3
54	Genetic testing in idiopathic interstitial pneumonia. , 2015, , .		0

#	Article	IF	Citations
55	A 12-week combination of clarithromycin and prednisone for the treatment of cryptogenic and radiation-induced organising pneumonia. , 2015, , .		0
56	Pulmonary manifestations revealing Rosai-Dorfman disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32, 275-7.	0.2	12
57	Angiogenesis stimulated by human kallikreinâ€related peptidase 12 actingviaa plateletâ€derived growth factor Bâ€dependent paracrine pathway. FASEB Journal, 2014, 28, 740-751.	0.2	33
58	Regulation of TGF-Î²1-driven Differentiation of Human Lung Fibroblasts. Journal of Biological Chemistry, 2014, 289, 16239-16251.	1.6	60
59	Human cystatin <scp>C</scp>: <scp>A</scp> new biomarker of idiopathic pulmonary fibrosis?. Proteomics - Clinical Applications, 2014, 8, 447-453.	0.8	15
60	New Selective Peptidyl Di(chlorophenyl) Phosphonate Esters for Visualizing and Blocking Neutrophil Proteinase 3 in Human Diseases. Journal of Biological Chemistry, 2014, 289, 31777-31791.	1.6	38
61	Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Series of 47 Western Patients. Journal of Thoracic Oncology, 2014, 9, 1162-1170.	0.5	61
62	Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. European Respiratory Review, 2014, 23, 193-214.	3.0	62
63	Pulmonary toxicity associated with the use of lenalidomide: Case report of late-onset acute respiratory distress syndrome and literature review. Heart and Lung: Journal of Acute and Critical Care, 2014, 43, 120-123.	0.8	8
64	Proteomic demonstration of the recurrent presence of inter-alpha-inhibitor H4 heavy-chain during aspergillosis induced in an animal model. International Journal of Medical Microbiology, 2014, 304, 327-338.	1.5	10
65	Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. Respiratory Medicine, 2014, 108, 1525-1533.	1.3	50
66	Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis). Seminars in Immunopathology, 2013, 35, 411-421.	2.8	57
67	Pulmonary Alveolar Proteinosis Revealing a Telomerase Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 402-404.	2.5	11
68	Comorbidities of COPD. European Respiratory Review, 2013, 22, 454-475.	3.0	353
69	Serious bronchopulmonary involvement due to chronic lymphocytic leukaemia. European Respiratory Review, 2013, 22, 416-419.	3.0	16
70	Monoclonal Anti-TNF-Î± Antibodies for Severe Steroid-Dependent Asthma: A Case Series. Open Respiratory Medicine Journal, 2013, 7, 21-25.	1.3	38
71	Hepatocyte Growth Factor and Lung Fibrosis. Proceedings of the American Thoracic Society, 2012, 9, 158-163.	3.5	52
72	Tracheal involvement in ulcerative colitis: clinical presentation and potential interest of 2-deoxy-2[18F]fluoro-d-glucose positron emission tomography (18F-FDG PET) for the management. Annals of Nuclear Medicine, 2012, 26, 830-834.	1.2	6

#	Article	IF	Citations
73	Hemodynamic Characteristics In 100 Patients With Precapillary Pulmonary Hypertension And Interstitial Lung Disease. , 2012, , .		0
74	A selective reversible azapeptide inhibitor of human neutrophil proteinase 3 derived from a high affinity FRET substrate. Biochemical Pharmacology, 2012, 83, 788-796.	2.0	21
75	Asthma Unmasked With Tumor Necrosis Factor-Î±-Blocking Drugs. Chest, 2011, 140, 1068-1071.	0.4	13
76	IV Immunoglobulin Might Be Considered as a First-line Treatment of Severe Interstitial Lung Disease Associated With Polymyositis. Chest, 2011, 140, 562-563.	0.4	21
77	Melanoma lymph node metastasis occurring simultaneously with multifocal sarcoidosis affecting lymph nodes and the lung: a diagnostic pitfall. European Journal of Dermatology, 2011, 21, 798-799.	0.3	6
78	Extracellular ATP Is a Danger Signal Activating P2X₇ Receptor in Lung Inflammation and Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 774-783.	2.5	362
79	Imbalance in the Proâ€“Hepatocyte Growth Factor Activation System in Bleomycin-Induced Lung Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 286-293.	1.4	14
80	Short- and long-term response to corticosteroid therapy in chronic beryllium disease. European Respiratory Journal, 2008, 32, 687-693.	3.1	24
81	Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax, 2008, 63, 251-258.	2.7	53
82	Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. European Respiratory Journal, 2008, 32, 426-436.	3.1	92
83	Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L334-L343.	1.3	61
84	Keratinocyte growth factor protects against elastase-induced pulmonary emphysema in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L1230-L1239.	1.3	56
85	Dendritic Cells Accumulate in Human Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1007-1014.	2.5	97
86	Diffuse Spine Involvement in Sarcoidosis With Sternal Lytic Lesions. Spine, 2007, 32, E594-E597.	1.0	22
87	Defect of Pro-Hepatocyte Growth Factor Activation by Fibroblasts in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 58-66.	2.5	57
88	HGF synthesis in human lung fibroblasts is regulated by oncostatin M. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L1097-L1103.	1.3	17
89	Cutting Edge: Nonproliferating Mature Immune Cells Form a Novel Type of Organized Lymphoid Structure in Idiopathic Pulmonary Fibrosis. Journal of Immunology, 2006, 176, 5735-5739.	0.4	157
90	Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. Journal of Nuclear Medicine, 2006, 47, 1281-7.	2.8	44

#	Article	IF	Citations
91	Defect of hepatocyte growth factor production by fibroblasts in human pulmonary emphysema. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L641-L647.	1.3	40
92	Keratinocyte Growth Factor Expression by Fibroblasts in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 470-477.	1.4	35
93	Defect of Hepatocyte Growth Factor Secretion by Fibroblasts in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1156-1161.	2.5	71
94	Ground-Glass Computed Tomography Pattern in Chronic Beryllium Disease: Pathologic Substratum and Evolution. Journal of Computer Assisted Tomography, 2003, 27, 496-500.	0.5	17
95	Severe Mechanical Dysfunction in Pharyngeal Muscle from AdultmdxMice. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 278-281.	2.5	22